PURPOSE: Blocking the Activin receptor type IIA and IIB (ActRIIA/IIB) has clinical potential to increase muscle mass and improve glycemic control in obesity, cancer, and aging. However, the impact of blocking ActRIIA/IIB on strength, metabolic regulation, and insulin action remains unclear. METHODS: Here, we investigated the effect of short- (10 mg kg(-1) bw, once, 40h) or long-term (10 mg kg(-1) bw, twice weekly, 21 days) antibody treatment targeting ActRIIA/IIB (αActRIIA/IIB) in lean and diet-induced obese mice and engineered human muscle tissue. RESULTS: Short-term α ActRIIA/IIB administration in lean mice increased insulin-stimulated glucose uptake in skeletal muscle by 76-105%. Despite this, αActRIIA/IIB-treated mice exhibited 33% elevated blood glucose and glucose intolerance. Long-term αActRIIA/IIB treatment increased muscle mass (+20%) and reduced fat mass (-8%) in obese mice but failed to enhance insulin-stimulated glucose uptake in muscle or adipose tissue. Instead, it induced glucose intolerance, cardiac hypertrophy with glycogen accumulation, and elevated hepatic triacylglycerol and glucose output in response to pyruvate. Concomitantly, long-term αActRIIA/IIB treatment increased strength (+30%) in mouse soleus muscle and prevented activin A-induced loss of tissue strength in engineered human muscle tissue. Surprisingly, long-term α ActRIIA/IIB treatment lowered volitional running (-250%). CONCLUSIONS: Our findings demonstrate that, in accordance with human studies, ActRIIA/IIB blockade holds promise for increasing muscle mass, strength, and muscle insulin sensitivity. However, contrary to the improved glycemic control in humans, ActRIIA/IIB blockade in mice causes severe glucose intolerance and lowers voluntary physical activity. Our study underscores the complex metabolic and functional consequences of ActRIIA/IIB blockade, and highlight species differences on glycemic control, which warrant further investigation.
Activin receptor type IIA/IIB blockade increases muscle mass and strength, but compromises glycemic control in mice.
阅读:1
作者:Carlsson Michala, Frank Emma, Mà rmol Joan M, Ali Mona Sadek, Raun Steffen H, Battey Edmund, Andersen Nicoline Resen, Irazoki Andrea, Lund Camilla, HenrÃquez-Olguin Carlos, Højfeldt Martina Kubec, Blomquist Pauline, Bromer Frederik Duch, Mocciaro Gabriele, Lodberg Andreas, Folsted Andersen Christian Brix, Eijken Marco, Fritzen Andreas Mæchel, Knudsen Jonas Roland, Richter Erik A, Sylow Lykke
| 期刊: | Molecular Metabolism | 影响因子: | 6.600 |
| 时间: | 2025 | 起止号: | 2025 Dec;102:102261 |
| doi: | 10.1016/j.molmet.2025.102261 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
